Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 491

1.

Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer disease.

Seo DO, Holtzman DM.

J Gerontol A Biol Sci Med Sci. 2019 Nov 18. pii: glz262. doi: 10.1093/gerona/glz262. [Epub ahead of print]

PMID:
31738402
2.

Dietary salt promotes cognitive impairment through tau phosphorylation.

Faraco G, Hochrainer K, Segarra SG, Schaeffer S, Santisteban MM, Menon A, Jiang H, Holtzman DM, Anrather J, Iadecola C.

Nature. 2019 Oct;574(7780):686-690. doi: 10.1038/s41586-019-1688-z. Epub 2019 Oct 23.

PMID:
31645758
3.

Targeting tauopathy with engineered tau-degrading intrabodies.

Gallardo G, Wong CH, Ricardez SM, Mann CN, Lin KH, Leyns CEG, Jiang H, Holtzman DM.

Mol Neurodegener. 2019 Oct 22;14(1):38. doi: 10.1186/s13024-019-0340-6.

4.

Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model.

Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM.

Mol Neurodegener. 2019 Oct 17;14(1):37. doi: 10.1186/s13024-019-0337-1.

5.

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model.

Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM.

J Exp Med. 2019 Nov 4;216(11):2546-2561. doi: 10.1084/jem.20190980. Epub 2019 Oct 10.

PMID:
31601677
6.

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Long JM, Holtzman DM.

Cell. 2019 Oct 3;179(2):312-339. doi: 10.1016/j.cell.2019.09.001. Epub 2019 Sep 26. Review.

PMID:
31564456
7.

The microbiome: A target for Alzheimer disease?

Seo DO, Boros BD, Holtzman DM.

Cell Res. 2019 Oct;29(10):779-780. doi: 10.1038/s41422-019-0227-7. No abstract available.

PMID:
31488883
8.

Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.

Wang C, Holtzman DM.

Neuropsychopharmacology. 2020 Jan;45(1):104-120. doi: 10.1038/s41386-019-0478-5. Epub 2019 Aug 13. Review.

PMID:
31408876
9.

Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains.

Xu J, Sun J, Perrin RJ, Mach RH, Bales KR, Morris JC, Benzinger TLS, Holtzman DM.

Ann Clin Transl Neurol. 2019 Aug;6(8):1423-1434. doi: 10.1002/acn3.50837. Epub 2019 Jul 9.

10.

A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain.

Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, Davenport R, Morris JC, Holtzman DM, Perrin RJ, Benitez BA, Dougherty J, Cruchaga C, Harari O.

Alzheimers Res Ther. 2019 Aug 9;11(1):71. doi: 10.1186/s13195-019-0524-x.

11.

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ.

Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1.

PMID:
31371569
12.

TREM2 function impedes tau seeding in neuritic plaques.

Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, Manis M, Colonna M, Lee VMY, Ulrich JD, Holtzman DM.

Nat Neurosci. 2019 Aug;22(8):1217-1222. doi: 10.1038/s41593-019-0433-0. Epub 2019 Jun 24.

PMID:
31235932
13.

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.

Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 May;15(5):655-665. doi: 10.1016/j.jalz.2018.12.019. Epub 2019 Mar 4.

PMID:
30846386
14.

Dural lymphatics regulate clearance of extracellular tau from the CNS.

Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D, Holtzman DM.

Mol Neurodegener. 2019 Feb 27;14(1):11. doi: 10.1186/s13024-019-0312-x.

15.

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.

Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019.

PMID:
30753379
16.

Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1.

Strickland MR, Holtzman DM.

J Clin Invest. 2019 Mar 1;129(3):969-971. doi: 10.1172/JCI127578. Epub 2019 Feb 11.

17.

Multi-Modal Home Sleep Monitoring in Older Adults.

Toedebusch CD, McLeland JS, Schaibley CM, Banks IR, Boyd J, Morris JC, Holtzman DM, Lucey BP.

J Vis Exp. 2019 Jan 26;(143). doi: 10.3791/58823.

PMID:
30741255
18.

Reply to "obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid".

Ju YS, Holtzman DM.

Ann Neurol. 2019 Mar;85(3):460-461. doi: 10.1002/ana.25424. Epub 2019 Feb 19. No abstract available.

PMID:
30706528
19.

The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.

Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM.

Science. 2019 Feb 22;363(6429):880-884. doi: 10.1126/science.aav2546. Epub 2019 Jan 24.

PMID:
30679382
20.

"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".

Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R.

Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. No abstract available.

PMID:
30642435
21.

Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.

Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM.

Sci Transl Med. 2019 Jan 9;11(474). pii: eaau6550. doi: 10.1126/scitranslmed.aau6550.

PMID:
30626715
22.

Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.

Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C.

Nat Neurosci. 2019 Feb;22(2):191-204. doi: 10.1038/s41593-018-0296-9. Epub 2019 Jan 7.

23.

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.

JAMA Neurol. 2019 Mar 1;76(3):264-273. doi: 10.1001/jamaneurol.2018.4249.

PMID:
30615028
24.

Obstructive sleep apnea treatment, slow wave activity, and amyloid-β.

Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM.

Ann Neurol. 2019 Feb;85(2):291-295. doi: 10.1002/ana.25408. Epub 2019 Jan 17.

PMID:
30597615
25.

New insights into the role of TREM2 in Alzheimer's disease.

Gratuze M, Leyns CEG, Holtzman DM.

Mol Neurodegener. 2018 Dec 20;13(1):66. doi: 10.1186/s13024-018-0298-9. Review.

26.

Amyloid-β 'seeds' in old vials of growth hormone.

Huynh TV, Holtzman DM.

Nature. 2018 Dec;564(7736):354-355. doi: 10.1038/d41586-018-07604-6. No abstract available.

PMID:
30546137
27.

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.

28.

High-affinity interactions and signal transduction between Aβ oligomers and TREM2.

Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE.

EMBO Mol Med. 2018 Nov;10(11). pii: e9027. doi: 10.15252/emmm.201809027.

29.

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.

Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV.

Mol Neurodegener. 2018 Oct 19;13(1):57. doi: 10.1186/s13024-018-0286-0.

30.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

31.

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

32.

Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Shi Y, Holtzman DM.

Nat Rev Immunol. 2018 Dec;18(12):759-772. doi: 10.1038/s41577-018-0051-1. Review.

33.

In Search of an Identity for Amyloid Plaques.

Huynh TV, Holtzman DM.

Trends Neurosci. 2018 Aug;41(8):483-486. doi: 10.1016/j.tins.2018.06.002.

PMID:
30053949
34.

Intercellular Spread of Protein Aggregates in Neurodegenerative Disease.

Davis AA, Leyns CEG, Holtzman DM.

Annu Rev Cell Dev Biol. 2018 Oct 6;34:545-568. doi: 10.1146/annurev-cellbio-100617-062636. Epub 2018 Jul 25. Review.

35.

Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP.

Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chávez-Gutiérrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, Tosh JL, Siganporia C, Whittaker HT, Stewart F, Szaruga M; London Down syndrome consortium, Murphy MP, Blennow K, de Strooper B, Zetterberg H, Bannerman D, Holtzman DM, Tybulewicz VLJ, Fisher EMC; LonDownS Consortium.

Brain. 2018 Aug 1;141(8):2457-2474. doi: 10.1093/brain/awy159. Erratum in: Brain. 2019 Jun 1;142(6):e25.

36.

Using the A/T/N Framework to Examine Driving in Preclinical AD.

Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC.

Geriatrics (Basel). 2018 Jun;3(2). pii: 23. doi: 10.3390/geriatrics3020023. Epub 2018 May 2. No abstract available.

37.

AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.

Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR.

Mol Neurodegener. 2018 May 15;13(1):22. doi: 10.1186/s13024-018-0256-6.

38.

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM; Dominantly Inherited Alzheimer Network.

PLoS One. 2018 May 9;13(5):e0195838. doi: 10.1371/journal.pone.0195838. eCollection 2018.

39.

Dual therapy for Aβ amyloidosis in AD: A successful one-two combo.

Patel TK, Holtzman DM.

J Exp Med. 2018 May 7;215(5):1267-1268. doi: 10.1084/jem.20180494. Epub 2018 Apr 23.

40.

Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.

Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA.

Brain. 2018 Jun 1;141(6):1828-1839. doi: 10.1093/brain/awy103.

41.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

42.

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.

Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM.

J Clin Invest. 2018 May 1;128(5):2144-2155. doi: 10.1172/JCI96429. Epub 2018 Mar 30.

43.

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.

Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM; ADNI.

Alzheimers Dement. 2018 Jul;14(7):869-879. doi: 10.1016/j.jalz.2018.01.012. Epub 2018 Mar 23.

44.

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM.

Alzheimers Dement. 2018 Nov;14(11):1460-1469. doi: 10.1016/j.jalz.2018.01.013. Epub 2018 Mar 2.

45.

ApoE facilitates the microglial response to amyloid plaque pathology.

Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM.

J Exp Med. 2018 Apr 2;215(4):1047-1058. doi: 10.1084/jem.20171265. Epub 2018 Feb 26.

46.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.

47.

Regulation of amyloid-β dynamics and pathology by the circadian clock.

Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES.

J Exp Med. 2018 Apr 2;215(4):1059-1068. doi: 10.1084/jem.20172347. Epub 2018 Jan 30.

48.

Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.

Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS.

JAMA Neurol. 2018 May 1;75(5):582-590. doi: 10.1001/jamaneurol.2017.4719.

49.

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM.

Nat Rev Neurol. 2018 Mar;14(3):168-181. doi: 10.1038/nrneurol.2017.185. Epub 2018 Jan 29. Review.

50.

Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers.

Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM.

Alzheimers Dement. 2018 May;14(5):610-616. doi: 10.1016/j.jalz.2017.11.011. Epub 2018 Jan 10.

Supplemental Content

Loading ...
Support Center